Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
about
Chaperones in hepatitis C virus infectionMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsVirologic Tools for HCV Drug Resistance TestingResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsThe New Era of Interferon-Free Treatment of Chronic Hepatitis CHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceHepatitis C virus: Virology, diagnosis and treatmentNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsDeconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.A Pan-HIV Strategy for Complete Genome Sequencing.Primer ID Validates Template Sampling Depth and Greatly Reduces the Error Rate of Next-Generation Sequencing of HIV-1 Genomic RNA Populations.Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugsNaturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.CD36 is a co-receptor for hepatitis C virus E1 protein attachment.Allosteric heat shock protein 70 inhibitors block hepatitis C virus assemblyComparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes.Hepatitis C, innate immunity and alcohol: friends or foes?Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Treatment of hepatitis C in difficult-to-treat patients.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Prevention and management of treatment failure to new oral hepatitis C drugs.Hepatitis C virus resistance to the new direct-acting antivirals.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment.The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.
P2860
Q26771251-8EBE43BE-DE4A-46DB-8EF1-339F574F2079Q26773321-0303B053-2175-48A2-B376-0F0670558222Q26774374-44BEFA03-06CC-40C2-94AC-BC1C52FABEC5Q26777408-56209AE4-4331-4A3A-866B-494FC7595D68Q26777716-76F662B2-3F07-4C0A-B836-5326F86ED087Q26779128-5E5175F1-9238-41AC-B10A-98F3192CA5F6Q26783056-5DF43946-2B8A-4423-ACBD-AB9E9172241DQ27469038-5EFD473A-D7C6-4E0B-8C68-0C59C3C8C7A5Q28082000-2BC437FF-648F-4EF6-A2E2-804E7941C31EQ28552134-43B70283-BAE1-48CE-BFF5-3FB39F3CA901Q28552269-289F9236-8D2F-4688-B56A-810ACD290E96Q35154587-EED381F2-21D9-4929-BEDA-056BD63F845CQ35501190-714E8E8D-6333-4EE4-8513-4EADA4ADBEACQ35759025-99FC94FE-5967-4878-8587-A88118128814Q35877301-CF5B8A9F-59D9-4F59-B28B-08853DEC2F19Q35914387-FF836B1F-F49E-44C9-BD37-B40B3818C3B7Q36096436-7A2E9353-AAC7-4B73-8F56-AC2C2C870571Q36290416-BEED659C-0897-436F-90CC-BD57FD87EF35Q36292486-B6A26E85-E789-469A-ADFF-5FC69593841EQ36531731-ECF9EE27-52EA-4738-BC82-E40BA5CCEE64Q36602246-21396F62-E933-4A85-A1E8-D40C3AFFDE78Q36803472-AAFF570F-BCB6-45CF-AF41-46CEA26D066FQ37280593-F9C7D88F-4069-4C5B-AF60-77DA5C01652FQ38349031-16CEE8FB-DCBC-4278-87E7-78C3B09D6D6EQ38381584-0719162A-7D8A-465E-B741-6759E0108796Q38431523-4F18CFB6-7F27-4FA4-A21C-BC391773D5EAQ38779980-995A7E72-0227-494F-9592-77C165415B96Q38826176-8CF3D6A8-50EB-4CF2-B072-406B46CAD1D5Q38826624-C19C1B4E-F857-4DEA-BA55-385D872BBBA2Q38887954-43A52B2A-2996-4675-9518-A10400D9496CQ38893104-8340A0C0-023B-4E63-9E06-4B91A93974B5Q38972180-D4766864-3313-4E6C-BB83-F4094E993628Q39301797-0EA1C05F-8CFD-406E-9FD4-89DE6BCDF0D1Q39307349-4EB0E1F4-BE01-41B9-A77F-EE56C701B77DQ39742470-AB54D485-BEDD-40A1-AACC-3D564A17D4F1Q40167095-76249B32-383D-4F6B-A177-4C4AFB4BCB8CQ40189279-D2390944-CB72-40B5-8D0E-F5148D556E42Q40278965-D3C0787D-9C97-4938-AC3D-595D64CBF262Q40301168-4F137B73-41F9-4279-A782-4D3DD1D55D32Q40326326-CF36864B-9866-4E4E-B204-617926DF255E
P2860
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@en
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@nl
type
label
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@en
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@nl
prefLabel
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@en
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@nl
P2093
P2860
P356
P1433
P1476
Clinical evidence and bioinfor ...... tance pathways for sofosbuvir.
@en
P2093
Eric F Donaldson
Julian J O'Rear
Lisa K Naeger
Patrick R Harrington
P2860
P356
10.1002/HEP.27375
P407
P577
2014-11-20T00:00:00Z